section name header

Pronunciation

be-si-FLOX-a-sin

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: Fluoroquinolones

Indications

REMS


Action

  • Inhibits bacterial DNA synthesis by inhibiting DNA gyrase.
Therapeutic effects:
  • Death of susceptible bacteria with decreased symptoms and sequelae of bacterial conjunctivitis.

Spectrum:

Pharmacokinetics

Absorption: Minimal absorption follows ophthalmic use.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 7 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
Ophthunknownunknown6–12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: conjunctival redness, blurred vision, eye irritation, eye pain, , eye pruritus.

Neuro: headache

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Besivance